Leidos Hld (LDOS) Stock Forecast & Price Target

Leidos Holdings is supported by strong 1Q26 execution, with adj. EPS of $3.13 topping consensus and revenues of $4.4B rising 4% YoY, while the recently closed ~$2.4B Entrust acquisition lifted 2026 guidance by $500M at the midpoint and helped sustain mid-13% adj. EBITDA margins. Its outlook is reinforced by durable demand in Health, strong veterans exam volumes, and growing exposure to defense-tech markets such as air defense, hypersonics, and unmanned ships, alongside $9B of defense tech awards over the last 15 months and visibility to another $8B over the NTM. Despite near-term uncertainty around Health and defense portfolios and a softer 2Q26, the firm’s attractive valuation, 1.0x LTM book-to-bill context, and margin/FCF upside potential support a constructive long-term view.

Leidos Holdings is challenged by heavy dependence on U.S. government spending, contract awards, and program execution, making its revenue and backlog vulnerable to annual budget decisions, shutdown overhangs, and sluggish award activity. Its 1Q26 results showed $4.40 billion of sales and 14.0% adjusted EBITDA margin, but the 0.8x book-to-bill signals weak order conversion, while management’s view that the quarter pulled forward revenue from 2Q26 suggests near-term growth may soften. The company also faces margin pressure from Health normalization and VA contract restructuring, alongside staffing, security, supply chain, inflation, and cyber risks that can impair margins and earnings quality.